BioSpace News Archive

Business

Carl Icahn Building Stake in Allergan Amidst Management Criticism

After two of Allergan’s investors, Appaloosa Management and Senator Investment Group, wrote to the company’s board asking that Brent Saunders’ duties be split up, legendary investor Carl Icahn appears to be building a position in the company—again.

June 7, 2018
·
3 min read
·
Mark Terry
Pharm Country

Johnson & Johnson to Sell Advanced Sterilization Products to Fortive for $2.8 Billion

Johnson & Johnson received a binding offer to sell its Advanced Sterilization Products (ASP) business to Fortive Corporation.

June 7, 2018
·
2 min read
·
Mark Terry
Business

Acorda Chief Says if it Loses Patent Appeals, No Sales Layoffs

In a recent interview, Ron Cohen, chief executive officer of Acorda Therapeutics, indicated that if the company lost its appeals over patent lawsuits for its Ampyra for multiple sclerosis, there would not be layoffs in its sales force.

June 7, 2018
·
2 min read
·
Mark Terry
FDA

Gottlieb at BIO 2018: 40 Gene Therapy Approvals by 2022

As the 2018 BIO International Convention wraps up in Boston today, it kicked off with a fireside chat with Dr. Scott Gottlieb, Commissioner of the U.S. Food and Drug Administration (FDA).

June 7, 2018
·
2 min read
·
Mark Terry
Business

Pfizer Pays BioMarin Pharma $20 Million Milestone

BioMarin Pharmaceutical received $20 million in milestone payments from Pfizer after the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) approved its applications for talazoparib.

June 7, 2018
·
3 min read
·
Mark Terry
Business

Luye to Continue Work with Elpis to Develop New CAR-T Therapies

Luye Pharma Group Ltd., announced today it is expanding its relationship with U.S. biotech firm Elpis Biopharmaceuticals Corp., to work on dual-target based therapies for cancer patients who fail to respond to current treatment.

June 7, 2018
·
2 min read
·
Don McCormick
Business

Biogen Options Stroke Drug from TMS in Deal That Could Hit $357 Million

Biogen signed an exclusive option deal with Tokyo-based TMS for TMS-007 and backup compounds.

June 7, 2018
·
2 min read
·
Mark Terry